Press Releases

BETHESDA, Md., December 26, 2024 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that on December 19, 2024 it entered into a $5 million convertible Promissory Note financing with YA II PN, Ltd., an investment fund managed by Yorkville Advisors Global, LP (“Yorkville”). The term of the Note... Read More

Over 77% Of All Shares Voted; Proposals Received Overwhelming Positive Votes BETHESDA, MD, July 3, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on June 29, 2024. Annual Meeting Results There was an exceptionally strong vote turnout at the 2023 Annual Meeting,... Read More

Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise BETHESDA, MD, June 17, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive Cancer Center for a... Read More

BETHESDA, MD, March 21, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024. Mr. Sarma will initially complete the remainder of Mr. Jerry Jasinowski’s term as an independent director, following Mr. Jasinowski’s retirement due... Read More

Accompanied by Broad Patent Coverage BETHESDA, MD, February 6, 2024 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the key development work for the Flaskworks manufacturing system has been completed and an external vendor has been engaged to produce GMP-grade units of the system. In addition, the patent coverage of the... Read More